Aktuellt
SENASTE
Redeye comments on Active Biotech’s Q4 report. The main event in the quarter was the oversubscribed rights issue. Laquinimod’s biodistribution study is the next main trigger while tasquinimod is slowly approaching the recruitment of the first patients in myelofibrosis.
LÄS MER
